...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Journal of Haematology >Allogeneic stem cell transplant in myelodysplastic syndrome‐factors impacting survival
【24h】

Allogeneic stem cell transplant in myelodysplastic syndrome‐factors impacting survival

机译：同种异体干细胞移植在骨髓增生综合征症中造成生存的影响因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Objectives The primary aim of this study was to evaluate survival outcomes following allo‐HCT in myelodysplastic syndrome (MDS), and the secondary aim was to study variables impacting survival. Methods This analysis describes patient characteristics, treatment, and outcomes in 125 consecutive adult patients with MDS transplanted from 2005 to 2018. Results The median age was 61?years, and median follow‐up in patients alive at last follow‐up was 29?months. The 2‐year OS and RFS were 39% (95%CI 30%‐48%) and 35.3% (95% CI: 27%‐44%), respectively. Transfusion dependence, high‐risk cytogenetics, and high serum ferritin were independent risk factors for death. The cumulative incidence of relapse (CIR) and non‐relapse mortality (NRM) at 2?years were 23% and 41.6%, respectively. High serum ferritin was significantly associated with NRM . There was no association between the percentage of bone marrow blasts (either at diagnosis or at pretransplant evaluation), on relapse or survival. Induction chemotherapy did not offer any survival advantage in MDS RAEB‐2 patients compared to cytoreduction with azacytidine alone. Conclusion Our results highlight the importance of karyotype on survival after allo‐HCT and identify serum ferritin and transfusion dependence as important surrogate markers of outcome. In addition, our results demonstrate the efficacy of azacytidine for pretransplant cytoreduction.
机译：摘要目的本研究的主要目的是评估骨髓增生综合征（MDS）中的Allo-HCT后的存活结果，二次目的是研究影响存活的变量。方法本分析描述了从2005年至2018年移植的MDS连续125名MDS中的患者特征，治疗和结果。结果中位年龄为61岁以下，患者在最后一次随访中的患者中的中位后续时间为29？几个月。 2年的OS和RFS分别为39％（95％CI 30％-48％）和35.3％（95％CI：27％-44％）。输血依赖性，高危细胞遗传学和高血清铁蛋白是死亡的独立危险因素。复发（CIR）和非复发死亡率（NRM）的累积发病率分别为23％和41.6％。高血清铁蛋白与NRM显着相关。骨髓爆炸百分比之间没有关联（在诊断或预挥发评估中），复发或存活。与单独的氮杂胞苷的胞嘧啶相比，诱导化疗没有为MDS Raeb-2患者提供任何存活的优势。结论我们的结果突出了核心型对血清 - HCT后生存率的重要性，并鉴定血清铁蛋白和输血依赖性，作为结果的重要替代标志。此外，我们的结果证明了氮杂胞苷对预体细胞抑制的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号